Beth Gardner

Senior Director, Patient Supply • Beam Therapeutics

Beth Gardner is Senior Director, Patient Supply at Beam Therapeutics (apheresis operations, autologous patient operations, and allogeneic clinical supplies).  She brings over 25 years of global pharma/biotech experience.  Her passion for helping people with medical needs began when she herself was diagnosed with a chronic disease as a child.  Now a bionic woman with technology to dose medication, she brings her passion and compassion for patients to Beam. Prior to Beam, Beth was at bluebird bio, supporting the development and commercialization of SkysonaTM and ZyntegloTM cell and gene therapies. 

Her personal goal is complex and cannot be done alone:  provide cell & gene therapies to patients with unmet medical needs.  Beyond Beam, Beth is energized by the impact she and her peers are making to create new industry standards: Apheresis Label for Further Manufacturing standards (ISBT-128 ST-018), Chain of Identity standards (ISBT-128 ST-028) and is a standing member of ICCBBA’s Cellular Therapy Coding and Labeling Advisory Group (CTCLAG). 

Outside the office, she keeps busy with her husband raising three sons (who like to reminder her that even at 6’2”, she will soon be the shortest in her family), maintains her sanity with Peloton rides, and despite now residing in Boston – remains a lifelong Chicago Cubs fan!

Beth holds an EMBA from Quantic School of Business and Technology; Executive Education certification from Massachusetts Institute of Technology (MIT), Sloan School of Management; Bachelor of Science from the University of Illinois.



Also Speaking

Samarendra Mohanty

Co-Founder and President • Nanoscope Therapeutics

Becky Johnson-Kent

Vice President, Europe & Women in Advanced Therapies (WiAT) Programme Lead • Phacilitate

Jeffrey Boyd

Partner, Global Healthcare & Life Sciences Practice • Heidrick & Struggles

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.